RTX-600

RTX-600 is an antibody-based therapeutic candidate currently in preclinical development by Resonant Therapeutics for the treatment of breast cancer and lung cancer. Identified using Resonant's proprietary platform, which focuses on discovering novel targets within the tumor microenvironment (TME), RTX-600 is designed to target a specific matrix receptor. Matrix receptors are critical mediators of the interaction between tumor cells and the extracellular matrix, influencing processes such as tumor growth, metastasis, and immune suppression. While the specific molecular identity of the target remains proprietary, RTX-600 aims to disrupt these oncogenic interactions. The therapeutic may be developed as a naked antibody, an antibody-drug conjugate (ADC), or a bispecific antibody, consistent with Resonant's broader development strategy.